Fosun International Ltd bought a new position in ViewRay, Inc. (NASDAQ:VRAY) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 111,132 shares of the company’s stock, valued at approximately $640,000. Fosun International Ltd owned approximately 0.19% of ViewRay at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of ViewRay by 158.7% during the 1st quarter. Geode Capital Management LLC now owns 149,463 shares of the company’s stock worth $1,271,000 after purchasing an additional 91,694 shares during the last quarter. UBS Group AG lifted its position in shares of ViewRay by 447.7% during the 1st quarter. UBS Group AG now owns 22,479 shares of the company’s stock worth $192,000 after purchasing an additional 18,375 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of ViewRay during the 1st quarter worth $484,000. Russell Investments Group Ltd. purchased a new stake in shares of ViewRay during the 2nd quarter worth $1,361,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of ViewRay during the 2nd quarter worth $323,000. 50.08% of the stock is currently owned by institutional investors and hedge funds.
Shares of ViewRay, Inc. (NASDAQ:VRAY) opened at $8.79 on Wednesday. ViewRay, Inc. has a 1 year low of $3.01 and a 1 year high of $10.39. The company has a quick ratio of 1.20, a current ratio of 1.59 and a debt-to-equity ratio of -1.67.
Several equities research analysts have recently issued reports on the stock. ValuEngine cut shares of ViewRay from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Mizuho reaffirmed a “buy” rating and set a $12.00 price objective on shares of ViewRay in a research report on Tuesday, September 26th. Finally, Northland Securities reaffirmed a “buy” rating and set a $10.00 price objective on shares of ViewRay in a research report on Friday, November 17th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. ViewRay has a consensus rating of “Buy” and a consensus target price of $10.60.
TRADEMARK VIOLATION NOTICE: “Fosun International Ltd Purchases New Position in ViewRay, Inc. (VRAY)” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2017/12/06/fosun-international-ltd-purchases-new-position-in-viewray-inc-vray.html.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.